The stability of meropenem in the presence of renal dehydropeptidase I (DHP-I) varied extremely with the animal source of the enzyme. Meropenem, compared with imipenem, was rather easily hydrolyzed by DHP-Is from mice, rabbits, and monkeys, while it showed a higher resistance to guinea pig and beagle dog DHP-Is. In addition, meropenem was four times more resistant than imipenem to human DHP-I. The 113-methyl substituent on carbapenems, i.e., meropenem and 1-methyl imipenem, made them considerably more resistant to mouse and swine DHP-Is than the 1-unsubstituted derivatives are.
The stability of meropenem in the presence of renal dehydropeptidase I (DHP-I) varied extremely with the animal source of the enzyme. Meropenem, compared with imipenem, was rather easily hydrolyzed by DHP-Is from mice, rabbits, and monkeys, while it showed a higher resistance to guinea pig and beagle dog DHP-Is. In addition, meropenem was four times more resistant than imipenem to human DHP-I. The 113-methyl substituent on carbapenems, i.e., meropenem and 1-methyl imipenem, made them considerably more resistant to mouse and swine DHP-Is than the 1-unsubstituted derivatives are.
During the last several years, a number of new ,4-lactam antibiotics have been introduced into clinical practice. Some of these antibiotics include carbapenems which are of particular interest. Discovery of thienamycin produced by Streptomyces cattleya (10) marked an epoch for 3-lactam antibiotics which have a wide antibacterial spectrum and high activity against gram-positive and gram-negative bacteria. Subsequently, a number of carbapenems, such as olivanic acids (3), carpetimycins (15) , asparenomycins (11) , and others, were discovered and some of them were chemically modified. However, none have been made available for clinical use except imipenem, an N-formimidoyl thienamycin. Imipenem and other related carbapenems were considerably inactivated by the renal enzyme dehydropeptidase I (DHP-I) (12, 14) . However, imipenem instability was overcome by coadministration of cilastatin, a specific DHP-I inhibitor (16) . This combination has been used to treat a variety of infections. Meropenem is a new carbapenem that is undergoing worldwide clinical trials by Sumitomo Pharmaceuticals and the ICI Pharmaceuticals group. One of its most prominent features is that it can be used alone, without any DHP-I inhibitor, since it is highly resistant to hydrolysis by human DHP-I. We investigated the resistance of meropenem to renal DHP-Is from various animal sources, including humans, in comparison with that of imipenem. The effect of 13-methyl substitution on resistance to DHP-I was also examined.
(Part of this study was presented previously [22] .) Meropenem and imipenem were prepared in the Research Laboratories of Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan. The other derivatives of meropenem and imipenem ( Fig. 1) and glycyldehydrophenylalanine (Gdp) were also synthesized in our laboratories.
Renal DHP-Is from various animal sources and humans were used in this study. Human from a Lineweaver-Burk plot. These determinations were performed in duplicate. Table 1 shows the kinetic parameters of hydrolysis of meropenem and imipenem by renal DHP-Is. The stability of these two carbapenems was determined from their VmaIKKm ratios. The resistance of meropenem to renal DHP-Is varied extremely with the animal source of the enzyme. Compared with imipenem, meropenem was easily hydrolyzed by mouse, rabbit, and rhesus monkey DHP-Is, while it showed greater resistance to guinea pig and beagle dog DHP-Is. In addition, meropenem was four times more resistant than imipenem to human DHP-I.
Meropenem and imipenem had almost the same affinities for various DHP-Is. In general, meropenem showed slightly higher affinity for these DHP-Is than did imipenem, although its affinities for mouse and rhesus monkey DHP-Is were about half of those of imipenem. On the other hand, the Vm.
values of these carbapenems differed markedly with the source of the enzyme. The Vm. of meropenem for guinea pig DHP-I was about 1/10 of that of imipenem, but it was 10 times higher for rhesus monkey DHP-I. The Vm. of meropenem for human DHP-I was 1 order of magnitude lower than that of imipenem, although it showed three times higher affinity for this DHP-I.
To assess the effect of 1B-methyl substitution on resistance to DHP-I, meropenem and imipenem were compared with desmethyl meropenem and 1l-methyl imipenem, respectively (Table 2) . In this study, we used mouse and swine DHP-Is. Since these enzymes had different substrate specificities and biochemical properties, mouse DHP-I more readily hydrolyzed meropenem and imipenem than Gdp. By contrast, swine DHP-I more readily hydrolyzed Gdp than meropenem and imipenem. In addition, these enzymes were clearly distinguished by their biochemical properties. Swine DHP-I was inactivated by EDTA and 1,10-phenanthroline, but the mouse enzyme was not (unpublished data).
Introduction (19) have already reported that the 13-methyl carbapenem antibiotics are highly resistant to renal DHP-I. Our results support his suggestion. In our previous study, the percentages of the dose of meropenem excreted in the urine after intravenous administration of 20 mg/kg were 34% in mice, 25% in rats, 43% in guinea pigs, 35% in rabbits, 43% in beagle dogs, and 26% in rhesus monkeys (22) . Meropenem had relatively high resistance to DHP-I from guinea pigs and beagle dogs, which is responsible for the comparatively high urinary recovery in these animals. On the other hand, the urinary recoveries of meropenem and imipenem in mice and rats were more than 20% (10), despite their low resistance to DHP-Is from these animals. This indicates that the carbapenems are excreted in the urine to some extent, even though they are well hydrolyzed by DHP-Is. This may be explained by the fact that the turnover rate of the carbapenem-hydrolyzing activity of DHP-I is relatively low compared with the renal clearance rate in those animals. It is also possible that urinary recovery of carbapenems is affected by the amount and localization of the enzyme in the kidneys (8) and/or the activity of extrarenal DHP-I (9, 21). On the whole, however, the more DHP-I-resistant carbapenems tend to have higher urinary recoveries.
As a carbapenem-hydrolyzing enzyme, DHP-I resembles the metalloenzyme 1-lactamases produced byXanthomonas maltophilia (17) , Flavobactenium odoratum (18), Bacteroides fragilis (6, 23) , and Aeromonas spp. (1) . At almost the same rate, these ,B-lactamases can hydrolyze any carbapenem, with or without a 1p-methyl group, as a substrate (data not shown). However, the activities of mouse and swine DHP-Is were affected by the 13-methyl substituent. We also studied the resistance of various analogs of meropenem and imipenem to these DHP-Is. However, the substrate specificities of none of the DHP-Is correlated well with those of human DHP-I for all of these analogous compounds. Swine DHP-I had a profile similar to that of human DHP-I, but it was a far-from-perfect match.
The present findings show that the 13-methyl substituent on meropenem confers higher resistance to renal DHP-I. In clinical trials of meropenem with healthy human volunteers, about 60 to 80% of the dose was excreted in the urine (2, 7) . This high urinary recovery is due to the high resistance of meropenem to human renal DHP-I.
